Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113,349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reply by Authors.
Gebrael G, Sayegh N, Tripathi N, Goel D, McFarland T, Ebrahimi H, Nordblad B, Chigarira B, Thomas VM, Sahu KK, Li H, Chehrazi-Raffle A, Kohli M, Agarwal N, Swami U, Maughan BL. Gebrael G, et al. Among authors: li h. Urol Pract. 2023 Oct 30:101097UPJ000000000000047102. doi: 10.1097/UPJ.0000000000000471.02. Online ahead of print. Urol Pract. 2023. PMID: 37903752 No abstract available.
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U. Sayegh N, et al. Among authors: li h. Eur Urol Focus. 2023 Jan;9(1):106-109. doi: 10.1016/j.euf.2022.06.015. Epub 2022 Jul 11. Eur Urol Focus. 2023. PMID: 35835693
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma.
Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Tripathi N, et al. Among authors: li h. Urol Oncol. 2022 Nov;40(11):493.e1-493.e7. doi: 10.1016/j.urolonc.2022.07.002. Epub 2022 Jul 30. Urol Oncol. 2022. PMID: 35918248
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: li h. J Urol. 2023 Apr;209(4):701-709. doi: 10.1097/JU.0000000000003132. Epub 2022 Dec 27. J Urol. 2023. PMID: 36573926
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: li h. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):279-282. doi: 10.1038/s41391-023-00696-w. Epub 2023 Jul 17. Prostate Cancer Prostatic Dis. 2024. PMID: 37460732
113,349 results
You have reached the last available page of results. Please see the User Guide for more information.